The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
Open accessAbstract
A growing number of human tumor antigens have been described that can be recognized by cytotoxic T lymphocytes (CTLs) in a major histocompatibility complex (MHC) class I–restricted fashion. Serological screening of cDNA expression libraries, SEREX, has recently been shown to provide another route for defining immunogenic human tumor antigens. The detection of antibody responses against known CTL-defined tumor antigens, e.g., MAGE-1 and tyrosinase, raised the question whether antibody and CTL responses against a defined tumor antigen can occur simultaneously in a single patient. In this paper, we report on a melanoma patient with a high-titer antibody response against the “cancer–testis” antigen NY-ESO-1. Concurrently, a strong MHC class I–restricted CTL reactivity against the autologous NY-ESO-1–positive tumor cell line was found. A stable CTL line (NW38-IVS-1) was established from this patient that reacted with autologous melanoma cells and with allogeneic human histocompatibility leukocyte antigen (HLA)-A2−, NY-ESO-1–positive, but not NY-ESO-1–negative, melanoma cells. Screening of NY-ESO-1 transfectants with NW38-IVS-1 revealed NY-ESO-1 as the relevant CTL target presented by HLA-A2. Computer calculation identified 26 peptides with HLA-A2–binding motifs encoded by NY-ESO-1. Of these, three peptides were efficiently recognized by NW38-IVS-1. Thus, we show that antigen-specific humoral and cellular immune responses against human tumor antigens may occur simultaneously. In addition, our analysis provides a general strategy for identifying the CTL-recognizing peptides of tumor antigens initially defined by autologous antibody.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Self-citationA testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y.-T., Scanlan, M. J., Sahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247
Self-citationA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Human neoplasms elicit multiple specific immune responses in the autologous host.
Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., & Pfreundschuh, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11810 · Cited by 1,078
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
Coulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1005 · Cited by 589
Cited by
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,325
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
Self-citationA Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
Stockert, E., Jäger, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., & Old, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1349 · Cited by 698
Self-citationThe role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
New Paths in Human Cancer Serology
Old, L. J., & Chen, Y.-T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1163 · Cited by 446
Self-citationRadiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
Self-citationDirected evolution of human T-cell receptors with picomolar affinities by phage display
Li, Y., Moysey, R., Molloy, P. E., Vuidepot, A.-L., Mahon, T., Baston, E., Dunn, S., Liddy, N., Jacob, J., Jakobsen, B. K., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1070 · Cited by 442
Davis, I. D., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403572101 · Cited by 440
Self-citationKnutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413497 · Cited by 426
Self-citationNY‐ESO‐1: Review of an Immunogenic Tumor Antigen
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95001-5 · Cited by 405
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
Jäger, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R., Lee, S. Y., Jungbluth, A., Jäger, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4760 · Cited by 398
Self-citationNY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 393
Tumor‐specific shared antigenic peptides recognized by human T cells
Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J., Van den Eynde, B. J., Brasseur, F., & Boon, T. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18806.x · Cited by 378
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Marie Nicolay, H. J., Sigalotti, L., & Maio, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.001 · Cited by 375
Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 365
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
Jungbluth, A. A., Chen, Y.-T., Stockert, E., Busam, K. J., Kolb, D., Iversen, K., Coplan, K., Williamson, B., Altorki, N., & Old, L. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1282 · Cited by 347
Self-citationYuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 332
Self-citationMonoclonal TCR-redirected tumor cell killing
Liddy, N., Bossi, G., Adams, K. J., Lissina, A., Mahon, T. M., Hassan, N. J., Gavarret, J., Bianchi, F. C., Pumphrey, N. J., Ladell, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2764 · Cited by 324
Oelke, M., Maus, M. V., Didiano, D., June, C. H., Mackensen, A., & Schneck, J. P. (2003) · Nature Medicine · doi:10.1038/nm869 · Cited by 306
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
DNA vaccine for cancer immunotherapy
Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C.-F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.980686 · Cited by 276
Sabbatini, P., Tsuji, T., Ferran, L., Ritter, E., Sedrak, C., Tuballes, K., Jungbluth, A. A., Ritter, G., Aghajanian, C., Bell-McGuinn, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2189 · Cited by 272
Self-citationOdunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E. W., Pan, L., Ritter, G., Villella, J., Thomas, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703342104 · Cited by 270
Self-citationThe role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity
Wang, R.-F. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01896-8 · Cited by 266
Structural and kinetic basis for heightened immunogenicity of T cell vaccines
Chen, J.-L., Stewart-Jones, G., Bossi, G., Lissin, N. M., Wooldridge, L., Choi, E. M. L., Held, G., Dunbar, P. R., Esnouf, R. M., Sami, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042323 · Cited by 262
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Natsume, A., Wakabayashi, T., Tsujimura, K., Shimato, S., Ito, M., Kuzushima, K., Kondo, Y., Sekido, Y., Kawatsura, H., Narita, Y., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23407 · Cited by 93
Rettig, L., Seidenberg, S., Parvanova, I., Samaras, P., Knuth, A., & Pascolo, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25756 · Cited by 83
Self-citationEvolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Albershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38
Phage display enables machine learning discovery of cancer antigen–specific TCRs
Croce, G., Lani, R., Tardivon, D., Bobisse, S., de Tiani, M., Bragina, M., Perez, M. A. S., Michaux, J., Pak, H. S., Michel, A., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads5589 · Cited by 23
Metadata
- Authors
- Jäger, E., Chen, Y.-T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jäger, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., & Knuth, A.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1998-01-19
- Volume
- 187
- Issue
- 2
- Pages
- 265-270
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2096385955
- Cited by
- 725
- References
- 23
- FWCI
- 12.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.